a developer of novel therapeutic compounds for diabetes and other diseases
Industry Biotechnology
A.I.dvisor tells us that DMAC and VICP have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DMAC and VICP's prices will move in lockstep.
Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
---|---|---|---|---|
DMAC | 100% | -3.29% | ||
VICP - DMAC | 33% Poorly correlated | N/A | ||
CYYNF - DMAC | 30% Poorly correlated | N/A | ||
CSLLY - DMAC | 26% Poorly correlated | -1.29% | ||
PCVX - DMAC | 26% Poorly correlated | -4.09% | ||
MCRB - DMAC | 24% Poorly correlated | +0.32% | ||
More |
Ticker / NAME | Correlation To DMAC | 1D Price Change % |
---|---|---|
DMAC | 100% | -3.29% |
diabetes theme (3 stocks) | 60% Loosely correlated | -1.10% |
drugs theme (254 stocks) | 14% Poorly correlated | -1.67% |
novel medical theme (11 stocks) | 11% Poorly correlated | -1.33% |
biotechnology theme (238 stocks) | 10% Poorly correlated | -1.76% |